SCHEMBL2477482

SCHEMBL2477482

O=[N+]([O-])c1cccc(-c2nn3c(c2-c2ccncc2)SCC3)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
LMNA P02545 2/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PDE4D Q08499 5/20 0.41
PDE4B Q07343 2/20 0.41
PDE4A P27815 2/20 0.41
PDE4C Q08493 2/20 0.41
ALOX5 P09917 1/20 0.40
CDC7 O00311 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476673 0.94 BCHE (0.44) BCHESMN1; SMN2LMNANPC1RAB9A
SCHEMBL2479421 0.81 FYN (0.41) CYP3A4SRCBRAF
SCHEMBL2478554 0.81 CYP17A1 (0.37) CYP3A4ALOX5ALDH1A1MEN1SRC
SCHEMBL2480280 0.79 KMO (0.40) SMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL2535199 0.78 BCHE (0.43) BCHESMN1; SMN2LMNANPC1RAB9A
SCHEMBL2477335 0.78 BRAF (0.47) NPC1RAB9AMAPTALOX5BRAF
SCHEMBL2481187 0.78 GRM5 (0.39) CYP1A2CYP3A4CYP2C19PDE4DCDC7
SCHEMBL2480248 0.74 MPO (0.39) SMN1; SMN2LMNANPC1RAB9AMAPT
SCHEMBL2477041 0.74 MPO (0.39) CYP3A4ALOX5MEN1SRCBRAF
SCHEMBL2478416 0.74 FYN (0.40) CYP3A4SRCBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 BCHE 3035/4885SMN1; SMN2 4275/4885LMNA 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.